Tales of how great drugs were brought down by a flawed rationale--letter.


In their recently published article (1), Komlodi-Pasztor and colleagues propose that development of selectivemitotic inhibitors is grounded in a flawed therapeutic rationale. The authors argue that the primary determinant of sensitivity is tumor cell proliferation rate, and that these drugs may prove efficacious only in highly proliferative disease. However… (More)
DOI: 10.1158/1078-0432.CCR-12-2695


  • Presentations referencing similar topics